Treosulfan FDA Approval Status
FDA Approved: No
Generic name: treosulfan
Company: Medexus Pharmaceuticals Inc.
Treatment for: Stem Cell Transplant Conditioning
Treosulfan is a bifunctional alkylating agent in development for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Development timeline for treosulfan
|Jul 25, 2022
|Treosulfan NDA Resubmitted to FDA
|Aug 3, 2021
|Complete Response Letter Received from FDA for Treosulfan
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.